HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of timolol on central corneal thickness.

AbstractPURPOSE:
Timolol is an effective and safe medication that is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea exhibits -adrenergic receptors, there are few studies available on the clinical impact of timolol on central corneal thickness (CCT).
METHODS:
Twenty healthy subjects were tested in a double-blind, prospective, and randomized study. Intraocular pressure (IOP) and CCT were measured before and during administration of timolol 0.5% eyedrops over 28 days.
RESULTS:
Administration of timolol 0.5% resulted in a reduction of IOP from an initial value of 16 ± 2 mm Hg to 13 ± 0 mm Hg (p<0.001, R2 = 0.7033) as well as an increase in CCT from 555 ± 11 µm from the time of the baseline examination to 567 ± 9 µm (p = 0.005, R2 = 0.8754), an increase of epithelial thickness from 53 ± 2 µm to 59 ± 3 µm (p<0.001, R2 = 0.5063), and an increase of stromal thickness from 494 ± 4 µm to 498 ± 9 µm (p = 0.045, R2 = 0.4352) after 9 days each. From day 10 on, a decrease in CCT (R2 = 0.6164), epithelial thickness (R2 = 0.2216), and stromal thickness (R2 = 0.2092) was observed. At the end, the values had returned toward the initial values measured (CCT 553 ± 8 µm, p = 0.391; epithelial thickness, 50 ± 2 µm, p = 0.214; and stromal thickness, 493 ± 8 µm, p = 0.483). In contrast, endothelial thickness did not vary following administration of timolol 0.5% (p = 0.727, R2 = 0.009).
CONCLUSIONS:
Topical administration of timolol 0.5% results in a reversible increase in CCT. These modest changes are unlikely to influence tonometry or clinical decision-making.
AuthorsMatthias Grueb, Jens Martin Rohrbach
JournalEuropean journal of ophthalmology (Eur J Ophthalmol) 2013 Nov-Dec Vol. 23 Issue 6 Pg. 784-8 ISSN: 1724-6016 [Electronic] United States
PMID23709328 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Adrenergic beta-Antagonists
  • Ophthalmic Solutions
  • Timolol
Topics
  • Administration, Topical
  • Adrenergic beta-Antagonists (administration & dosage)
  • Adult
  • Cornea (drug effects, pathology)
  • Double-Blind Method
  • Female
  • Healthy Volunteers
  • Humans
  • Intraocular Pressure (drug effects)
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Prospective Studies
  • Timolol (administration & dosage)
  • Tomography, Optical Coherence
  • Tonometry, Ocular (methods)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: